Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
